USANA Health Sciences reported second-quarter results that missed Wall Street expectations, with revenue of $223.3 million versus analyst estimates of $235 million and an adjusted loss per share of $0.07 compared to the expected $0.43 profit. Management attributed the underperformance to a non-cash goodwill impairment in its Hiya business and a packaging issue at Rise Wellness, while the core nutritional segment showed stability with strength in Mainland China offsetting declines elsewhere. During the earnings call, analysts from Sidoti & Company and Tigress Financial Partners pressed executives on the sustainability of China's sales uptick, the causes of North Asia's revenue decline, Hiya's direct subscription performance, the financial impact of Rise Wellness's packaging issue, and the company's evolution toward omni-channel distribution. The company reconfirmed its full-year revenue guidance of $962.5 million at the midpoint and reiterated adjusted EPS guidance of $2.12 at the midpoint, with EBITDA guidance of $105 million at the midpoint.
USANA Health Sciences IncQ2 revenue and EPS missed estimates, with adjusted loss per share of $0.07 vs expected profit.
Non-cash goodwill impairment in Hiya business contributed to the earnings miss.
